126 related articles for article (PubMed ID: 8707747)
1. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis.
Zanetti S; Usai D; Nonis A; Fadda G
J Antimicrob Chemother; 1996 Feb; 37(2):357-9. PubMed ID: 8707747
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.
Jones RB; Ridgway GL; Boulding S; Hunley KL
Rev Infect Dis; 1983; 5 Suppl 3():S556-61. PubMed ID: 6635445
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains.
Zanetti S; Ungheri D; Castellani Pastoris M; Fadda G
Drugs Exp Clin Res; 1987; 13(10):631-4. PubMed ID: 3428127
[TBL] [Abstract][Full Text] [Related]
4. [Susceptibility study on urogenital Chlamydia trachomatis to 19 kinds of antibiotics].
Bai H; Dong J; Ning B
Zhonghua Yi Xue Za Zhi; 1995 Jan; 75(1):11-4, 60. PubMed ID: 7600311
[TBL] [Abstract][Full Text] [Related]
5. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis.
Prasad ES; Wenman WM
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):135-6. PubMed ID: 8467625
[TBL] [Abstract][Full Text] [Related]
7. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
[TBL] [Abstract][Full Text] [Related]
8. The antibacterial activity of a new 3-azinomethyl-rifamycin.
Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
10. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
Suchland RJ; Bourillon A; Denamur E; Stamm WE; Rothstein DM
Antimicrob Agents Chemother; 2005 Mar; 49(3):1120-6. PubMed ID: 15728912
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin.
Treharne JD; Yearsley PJ; Ballard RC
Antimicrob Agents Chemother; 1989 Aug; 33(8):1393-4. PubMed ID: 2552911
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565).
Dickinson JM; Mitchison DA
Tubercle; 1990 Jun; 71(2):109-15. PubMed ID: 2120827
[TBL] [Abstract][Full Text] [Related]
13. Relative resistance to erythromycin in Chlamydia trachomatis.
Mourad A; Sweet RL; Sugg N; Schachter J
Antimicrob Agents Chemother; 1980 Nov; 18(5):696-8. PubMed ID: 7447426
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.
Walsh M; Kappus EW; Quinn TC
Antimicrob Agents Chemother; 1987 May; 31(5):811-2. PubMed ID: 3038010
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of dirithromycin against Chlamydia trachomatis.
Segreti J; Kapell KS
Antimicrob Agents Chemother; 1994 Sep; 38(9):2213-4. PubMed ID: 7811051
[TBL] [Abstract][Full Text] [Related]
16. [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice].
Sternak SL; Skerk V
Med Glas (Zenica); 2010 Feb; 7(1):26-31. PubMed ID: 20387721
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of fleroxacin against Chlamydia trachomatis.
Steele-Mortimer O; Meier-Ewert H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
[TBL] [Abstract][Full Text] [Related]
18. Effective inhibition of rifampicin-resistant Chlamydia trachomatis by the novel DNA-dependent RNA polymerase inhibitor corallopyronin A.
Shima K; Ledig S; Loeper N; Schiefer A; Pfarr K; Hoerauf A; Graspeuntner S; Rupp J
Int J Antimicrob Agents; 2018 Oct; 52(4):523-524. PubMed ID: 30092271
[No Abstract] [Full Text] [Related]
19. In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains.
Miyashita N; Matsumoto A; Matsushima T
Microbiol Immunol; 2000; 44(4):267-9. PubMed ID: 10832970
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of dirithromycin against Chlamydia pneumoniae.
Roblin PM; Kutlin A; Sokolovskaya N; Hammerschlag MR
J Antimicrob Chemother; 1997 May; 39(5):647-9. PubMed ID: 9184366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
